So here's the thing about earnings season: sometimes a company can deliver perfectly fine quarterly results and still see its stock get hammered. That's what happened to Abbott Laboratories (ABT) on Thursday. The healthcare giant reported first-quarter numbers that actually beat expectations, but then it went and cut its full-year outlook. Investors, being the forward-looking bunch they are, decided to focus on the future guidance rather than the past performance, and the stock dropped nearly 5% to a fresh 52-week low.

Let's break it down. For the quarter, Abbott posted sales of $11.16 billion, which was a bit better than the $10.99 billion analysts were expecting. On the bottom line, adjusted earnings came in at $1.15 per share, topping the Wall Street estimate of $1.14. Sales grew 7.8% on a reported basis, or 3.7% if you adjust for the recent acquisition of Exact Sciences. So far, so good.

The real story, though, is in the segments. The Medical Devices business was the star, with sales jumping 13.2% to $5.54 billion (or 8.5% on a comparable basis). Growth was led by double-digit increases in areas like Electrophysiology and Heart Failure. Over in Diabetes Care, sales were around $2.08 billion, with continuous glucose monitors growing 14.2% reported and 7.6% comparable. That's the kind of performance that usually gets investors excited.

But not everything was firing on all cylinders. Diagnostics sales increased 6.1% to $2.18 billion, but that growth was a bit mixed. Core Laboratory Diagnostics did well, driven by strength in the U.S., Europe, and Latin America. However, Rapid and Molecular Diagnostics felt the pinch from a weaker respiratory virus season compared to last year—fewer sick people means fewer tests sold. Then there's the Nutrition division, where sales actually decreased 6% to $2.02 billion, hurt by lower sales volumes and some pricing actions taken late last year. Established Pharmaceuticals was a bright spot, with sales up 13.2%.

Now, about that guidance cut. Abbott said it now expects second-quarter adjusted earnings of $1.25 to $1.31 per share, which is below the consensus estimate of $1.37. More importantly, it lowered its full-year 2026 adjusted earnings outlook from a range of $5.55-$5.80 per share down to $5.38-$5.58. Wall Street was looking for about $5.62, so this new range is a step down. The company did note that the updated guidance includes about 20 cents per share of dilution related to the Exact Sciences acquisition. For the full year, Abbott is projecting comparable sales growth of 6.5% to 7.5%.

On the investor call, Chairman and CEO Robert Ford addressed the elephant in the room. "We forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate," he said. In other words, the deal might be dilutive in the short term, but the company is betting it will pay off over the long haul.

Investors, however, seemed more focused on the near-term numbers. Abbott shares were down 4.76% at $96.72, hitting a new 52-week low. Sometimes the market is a game of expectations, and today, Abbott's revised forecast simply didn't meet them.